Buying Bayer Rights, Celera Axes Axys Collaboration | GenomeWeb

NEW YORK, Oct. 8 - Celera Genomics has bought from Bayer all rights to preclinical research held under an existing collaboration between the two companies. In the process, Celera has untied a research partnership in place since before the Applera unit bought Axys Pharmaceuticals last year.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.